ArticleInfluenza and other respiratory viruses2026
Characteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021-2024) in Valladolid, Spain. The VALLAVIRUS Study.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHuman metapneumovirus (hMPV) is a respiratory pathogen often underestimated in the elderly. Although studies suggest it causes around 10% of respiratory hospitalizations in the United States, national and local data remain scarce. This study aimed to describe patients hospitalized with hMPV and identify risk factors for hospitalization and severe disease.
methodsA retrospective study included adults aged ≥ 60 years diagnosed with hMPV infection in two hospitals in Valladolid, Spain, during three consecutive seasons (2021-2024). Data on demographics, comorbidities, clinical presentation, laboratory results and severity parameters were collected. Severe disease was defined as hospital stay ≥ 11 days, ICU admission, need for mechanical ventilation, readmission within 90 days or in-hospital death.
resultsAmong 703 hMPV-confirmed cases, 608 required hospitalization, following a clear seasonal epidemic pattern (November-March). The hospitalization rate was 123.2 per 100,000 > 60 years old inhabitants (95% CI: 113.6-133.4), representing 20.5% of respiratory virus detections. Mean hospital stay was 10.5 days; 6.4% of the patients were admitted to ICU, 3.3% required mechanical ventilation, 6.9% died, and 14.0% were readmitted within 90 days. Advanced age (≥ 75 years) increased hospitalization risk threefold to fivefold compared to people between 60 and 74 years old. Co-infections, particularly bacterial, and living in nursing homes were also associated with a 1.5-2.7 fold higher risk of severe disease and hospitalization.
conclusionshMPV infections pose a significant health burden among the elderly. The findings underscore the need for greater awareness, surveillance, and development of preventive strategies, including vaccination, against hMPV in older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.